Beyond basic science, the promise of parallel computing is the ability to model multiple variants simultaneously, bringing this systematic insight to medical questions. Precision medicine seeks to optimize patient-therapeutic pairings using patient mutation profiles, but this promise remains unfulfilled. From the NCI-MATCH clinical trial, only 18% of patient tumor categories have the necessary annotations to pair optimal clinical treatments to patients. . Even in cases where sufficient functional data exists to generate targeted treatments, only 30% of patients have experienced an improvement in clinical outcomes, highlighting the need for improved functional annotation . Thus, only 6% of the cancer patient population currently experiences improved clinical outcomes from precision oncology practices . Scarcity in clinical improvement is explained by an absence of mechanistic information describing clinically observed mutants, making it challenging to know whether a mutation is an disease driver or resists clinically used inhibitors.